Table 1.

Patient demographic data

	Case 1	Case 2	Case 3
Demographics	43-year-old African American man	53-year-old African American woman	48-year-old African American woman
Other organ involvement	Pulmonary	Pulmonary and eye	Pulmonary and eye
Cutaneous features at diagnosis	Nodular lesions on face, eyelids, and earlobes	Multiple erythematous to violaceous papules on eyelids, right cheek, tip of nose, and corner of mouth	Multiple erythematous annular plaques around eyes, nose, perioral area, neck, arm, back and knees
Histopathology	From right cheek: granulomatous inflammatory infiltrate (lymphocytes, histiocytes, and giant cells)	From right cheek: non-necrotizing granulomas (epithelioid cells and multinucleated giant cells)	N/A
Previous treatment before initiating infliximab	Prednisone Hydroxychloroquine Intralesional corticosteroids	Prednisone Hydroxychloroquine Methotrexate Minocycline Topical tacrolimus Topical imiquimod Mycophenolate mofetil	Prednisone Hydroxychloroquine Methotrexate Pulse methyl prednisone Thalidomide Topical corticosteroids
Therapeutic side effects or complications	A significant amount of weight gain Hypertension New onset diabetes A spontaneous hairline left 5th metatarsal fracture	Hypertension Diabetes Right hip avascular necrosis	Corticosteroids-induced gastrointestinal upset, fatigue Hydroxychloroquine-induced diarrhea and abdominal pain Methotrexate-induced leucopenia and abnormal liver function tests Thalidomide-induced peripheral neuropathy
Duration of disease before infliximab therapy	2 years	18 years	8 years
Treatments used at the time of infliximab initiation	Hydroxychloroquine (200 mg twice a day) Intralesional corticosteroids	Mycophenolate mofetil (4 g/day) Prednisone (15 mg/day)	Prednisone (40 mg/day) Thalidomide (100 mg/day)
Infliximab dose, duration	5 mg/kg on weeks 0, 2, and 6, then every 8 weeks 6 months later: add methotrexate 7.5 mg weekly after tapering prednisone 6 months later increased infliximab to 5 mg/kg and 7.5 mg/kg every 7 weeks 9 months later increased infliximab to 10 mg/kg every 5 weeks	7.5 mg/kg on weeks 0, 2, and 6, then every 8 weeks	7.5 mg/kg on weeks 0, 2, and 6, then every 8 weeks 4 years later tapered to 5 mg/kg every 16 weeks 3 years later taken off infliximab
Time to achieve clinical response	3 years	5 months	4 years
Treatments at the time of last follow-up	Infliximab (10 mg/kg every 5 weeks) Methotrexate (7.5 mg weekly) Prednisone (2.5 mg/day every other day)	Infliximab (7.5 mg/kg every 8 weeks)	Discontinued infliximab
Follow-up	Still gradually increase new lesions	Improvement after mycophenolate mofetil and prednisone discontinuation	No new lesions